- Home
- YSG vs ATXS Comparison
YSG vs ATXS Comparison
Compare YSG & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSG | ATXS |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.0M | 732.4M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | YSG | ATXS |
|---|---|---|
| Price | $4.16 | $12.58 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 133.1K | ★ 793.4K |
| Earning Date | 02-24-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $571,300,568.00 | $706,000.00 |
| Revenue This Year | $28.96 | N/A |
| Revenue Next Year | $16.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.59 | N/A |
| 52 Week Low | $3.12 | $3.56 |
| 52 Week High | $11.57 | $13.29 |
Technical Indicators
Market Signals| Indicator | YSG | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 46.10 |
| Support Level | $4.11 | $12.24 |
| Resistance Level | $4.62 | $12.86 |
| Average True Range (ATR) | 0.30 | 0.25 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 24.32 | 32.54 |
Price Performance
Historical ComparisonAbout YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.